Patient feedback and behaviors that affect clinical outcomes (e.g. adherence, therapeutic decisions, synergistic drugs, etc.) are not tracked and aggregated across similar disease communities.

The classic drug development paradigm is expensive (>$1.1B), takes a long time (8+ years), and doesn’t emphasize continuous, real-world outcome data to further refine research and development for additional patient populations.

The one-size-fits-all approach to drug and diagnostic development no longer fits into a highly competitive healthcare framework that demands more precise therapeutic solutions.